[伊马提尼布诱发EDEMA] 这一药物
Dmitriy Olshanskiy1, Hen Ben Varon1, Meir Mouallem1
1Department of Medicine E, Sheba Medical Center Tel-Hashomer, affiliated to Faculty of Medicine, Tel-Aviv University Israel.
伊马替尼 (Imatinib) 是一种白血病药物,可能会导致流体保留和周围耳道. 这一案例凸显了氨酸激酶抑制剂在CML治疗中的潜在副作用.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 伊马替尼是自2002年以来批准用于慢性髓性白血病 (CML) 治疗的铁氨酸激酶抑制剂.
- 慢性骨髓性白血病是一种骨髓扩散性瘤.
更多相关视频
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Mitogens and the Cell Cycle
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
